MPS Pharmaa approves FY26 financials and director reappointments
- MPS Pharmaa approved audited standalone financial statements for FY26 at its 32nd AGM
- Ram Niwas Sharma was reappointed as Director following retirement by rotation
- Nemani Garg Agarwal & Co. was reappointed as Statutory Auditors
- Anchal Goyal was appointed as Independent Director via special resolution
- Related party transactions under Section 188 were approved by shareholders
*this image is generated using AI for illustrative purposes only.
MPS Pharmaa Limited approved its audited standalone financial statements for the financial year ended March 31, 2026, during its 32nd Annual General Meeting held on September 29, 2026. The meeting also ratified the reappointment of a director and statutory auditors.
The company, formerly known as Advik Laboratories Limited, convened the meeting in New Delhi. Peeyush Kumar Aggarwal served as the Chairman for the session. The Board presented the Balance Sheet, Statement of Profit and Loss, Cash Flow Statement, and the Directors' Report to the shareholders.
Resolutions passed
Shareholders voted on six items of business, comprising ordinary and special resolutions. The key approvals included:
| Business Item | Nature of Resolution |
|---|---|
| Adoption of audited financial statements for FY26 | Ordinary |
| Reappointment of Ram Niwas Sharma as Director | Ordinary |
| Reappointment of Nemani Garg Agarwal & Co. as Statutory Auditors | Ordinary |
| Approval of Related Party Transactions under Section 188 | Ordinary |
| Appointment of Anchal Goyal as Independent Director | Special |
| Approval of Transactions under Section 185 | Special |
Ram Niwas Sharma was liable to retire by rotation and offered himself for reappointment under Section 152 of the Companies Act, 2013. The appointment of Anchal Goyal as an Independent Director required a special resolution, which was duly passed.
Voting and compliance
The meeting utilized remote e-voting facilities, which closed on September 28, 2026. Shareholders present in person cast votes via ballot forms supervised by Kundan Agarwal, a practicing company secretary appointed as Scrutinizer. The combined voting results were scheduled for disclosure to stock exchanges and regulatory bodies within two working days.
The proceedings concluded with the Chairman thanking shareholders and employees for their support. The intimation was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
How will the rebranding from Advik Laboratories to MPS Pharmaa influence the company's market positioning and investor perception in the pharmaceutical sector?
What specific strategic initiatives are expected to be driven by the newly appointed Independent Director, Anchal Goyal, to enhance corporate governance?
What are the projected financial impacts of the approved related party transactions on MPS Pharmaa's operational efficiency and profitability for FY27?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
